Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $3.2 million.

  • Allogene Therapeutics' Cash from Financing Activities rose 37658.32% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 7475.76%. This contributed to the annual value of $116.7 million for FY2024, which is 2192.38% up from last year.
  • Allogene Therapeutics' Cash from Financing Activities amounted to $3.2 million in Q3 2025, which was up 37658.32% from $5.1 million recorded in Q2 2025.
  • Allogene Therapeutics' Cash from Financing Activities' 5-year high stood at $108.6 million during Q2 2024, with a 5-year trough of $24000.0 in Q2 2022.
  • Its 5-year average for Cash from Financing Activities is $13.1 million, with a median of $2.4 million in 2021.
  • In the last 5 years, Allogene Therapeutics' Cash from Financing Activities crashed by 9946.45% in 2021 and then soared by 37291666.67% in 2023.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Cash from Financing Activities stood at $322000.0 in 2021, then tumbled by 85.71% to $46000.0 in 2022, then soared by 236.96% to $155000.0 in 2023, then soared by 3605.16% to $5.7 million in 2024, then plummeted by 43.65% to $3.2 million in 2025.
  • Its Cash from Financing Activities stands at $3.2 million for Q3 2025, versus $5.1 million for Q2 2025 and $14.0 million for Q1 2025.